nivolumab,sintilimab
bms,eli lilly
['nadim', 'lcsm,(-blcsm)', 'nadimii']
randomized phase ii trial #neoscore for #neoadjuvant chemo + #sintilamab 2 vs. 3 cycles for stage ib-iiia major pathological response (mpr) 26.9% vs. 41.4% (notable more mpr in squamous) #lcsm #asco2022 nadimii trial data (presented next) 
Fellowship Program Director ????? Hematology & Oncology at George Washington University. Thoracic and Head&Neck cancer.